Application of a colorectal cancer ctDNA methylation test in endocrine cancers

Jean M. Winter; Lorraine Sheehan-Hennessy; Susanne Kartin Pedersen; Molla M. Wassie; Graeme P. Young; Erin L. Symonds

doi:10.1200/JCO.2021.39.15_suppl.e15533

Application of a colorectal cancer ctDNA methylation test in endocrine cancers

Jean M. Winter
, Lorraine Sheehan-Hennessy
, Susanne Kartin Pedersen
, Molla M. Wassie
, Graeme P. Young
, Erin L. Symonds

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Background: Assays for circulating tumor DNA (ctDNA) have shown utility for cancer detection and management. It is important to demonstrate cancer specificity of targeted ctDNA biomarkers. Detection of methylated BCAT1 and IKZF1 ctDNA has shown high sensitivity for colorectal cancer (CRC). The aim of this study was to investigate whether hypermethylation of these two biomarkers is also present in prostate or breast adenocarcinoma (PCa or BCa) tissues, and if they are detectable as ctDNA from such cancer patients.

Original language	English
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	39
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.e15533
Publication status	Published - 20 May 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

circulating
tumor
DNA
ctDNA
cancer
methylated
endocrine
prostate
breast
colonoscopy

Access to Document

10.1200/JCO.2021.39.15_suppl.e15533Licence: In Copyright

Cite this

@article{72749ccdb5cb46c9a013f7ded7c1abd7,

title = "Application of a colorectal cancer ctDNA methylation test in endocrine cancers",

abstract = "Background: Assays for circulating tumor DNA (ctDNA) have shown utility for cancer detection and management. It is important to demonstrate cancer specificity of targeted ctDNA biomarkers. Detection of methylated BCAT1 and IKZF1 ctDNA has shown high sensitivity for colorectal cancer (CRC). The aim of this study was to investigate whether hypermethylation of these two biomarkers is also present in prostate or breast adenocarcinoma (PCa or BCa) tissues, and if they are detectable as ctDNA from such cancer patients.",

keywords = "circulating, tumor, DNA, ctDNA, cancer, methylated, endocrine, prostate, breast, colonoscopy",

author = "Winter, \{Jean M.\} and Lorraine Sheehan-Hennessy and Pedersen, \{Susanne Kartin\} and Wassie, \{Molla M.\} and Young, \{Graeme P.\} and Symonds, \{Erin L.\}",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15\_suppl.e15533",

language = "English",

volume = "39",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "15",

}

TY - JOUR

T1 - Application of a colorectal cancer ctDNA methylation test in endocrine cancers

AU - Winter, Jean M.

AU - Sheehan-Hennessy, Lorraine

AU - Pedersen, Susanne Kartin

AU - Wassie, Molla M.

AU - Young , Graeme P.

AU - Symonds, Erin L.

PY - 2021/5/20

Y1 - 2021/5/20

N2 - Background: Assays for circulating tumor DNA (ctDNA) have shown utility for cancer detection and management. It is important to demonstrate cancer specificity of targeted ctDNA biomarkers. Detection of methylated BCAT1 and IKZF1 ctDNA has shown high sensitivity for colorectal cancer (CRC). The aim of this study was to investigate whether hypermethylation of these two biomarkers is also present in prostate or breast adenocarcinoma (PCa or BCa) tissues, and if they are detectable as ctDNA from such cancer patients.

AB - Background: Assays for circulating tumor DNA (ctDNA) have shown utility for cancer detection and management. It is important to demonstrate cancer specificity of targeted ctDNA biomarkers. Detection of methylated BCAT1 and IKZF1 ctDNA has shown high sensitivity for colorectal cancer (CRC). The aim of this study was to investigate whether hypermethylation of these two biomarkers is also present in prostate or breast adenocarcinoma (PCa or BCa) tissues, and if they are detectable as ctDNA from such cancer patients.

KW - circulating

KW - tumor

KW - DNA

KW - ctDNA

KW - cancer

KW - methylated

KW - endocrine

KW - prostate

KW - breast

KW - colonoscopy

U2 - 10.1200/JCO.2021.39.15_suppl.e15533

DO - 10.1200/JCO.2021.39.15_suppl.e15533

M3 - Meeting Abstract

SN - 0732-183X

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

Application of a colorectal cancer ctDNA methylation test in endocrine cancers

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this